` PCK (PainChek Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PCK
vs
S
S&P/ASX 300

Over the past 12 months, PCK has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +9% growth.

Stocks Performance
PCK vs S&P/ASX 300

Loading
PCK
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
PCK vs S&P/ASX 300

Loading
PCK
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
PCK vs S&P/ASX 300

Loading
PCK
S&P/ASX 300
Add Stock

Competitors Performance
PainChek Ltd vs Peers

S&P/ASX 300
PCK
VEEV
PME
DOCS
2413
Add Stock

PainChek Ltd
Glance View

Market Cap
72.3m AUD
Industry
Health Care

PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.

PCK Intrinsic Value
0.004 AUD
Overvaluation 90%
Intrinsic Value
Price
Back to Top